-
Elmiron Pigmentary Maculopathy Risk Warning Issued by Janssen and Health Canada in December 2020
New Medical Article Describes How to Identify, Image, and Diagnose Pigmentary Maculopathy Caused by Elmiron Use (Posted by Tom Lamb at Drug Injury Watch) On December 15, 2020 a Dear Healthcare Professional…
-
Novartis Update on Patients Suffering from Retinal Vasculitis and/or Retinal Vascular Occlusion After Beovu Injections
November 2020 Report: Beovu Eye Side Effects Risks Higher for Beovu Patients with Prior Intraocular Inflammation and/or Vascular Occlusion (Posted by Tom Lamb at DrugInjuryWatch.com) We have known since early 2020 that…
-
Gilenya Safety Alert November 2020: Cases of Acute Liver Failure Requiring Liver Transplant
European Medicines Agency (EMA) and Novartis Issue Dear Doctor Letter About Gilenya Label Change (Posted by Tom Lamb at DrugInjuryWatch.com) A recent periodic review of Gilenya safety data by the European Medicines…
-
Beovu Lawsuits Filed Against Novartis for Patients Who Have Suffered Vision Loss Side Effects
Beovu Legal Cases Involve Retinal Artery Occlusion, Retinal Vasculitis, Intraocular Inflammation, Other Eye Problems (Posted by Tom Lamb at DrugInjuryWatch.com) Beovu (brolucizumab) is prescribed for the treatment of neovascular (wet) age-related macular…